Flavonoid rich dark cocoa may improve fatigue in people with multiple sclerosis, yet has no effect on glycaemic response: An exploratory trial by Coe, Shelly et al.
Abstract 1 
Context: Current research suggests that dark cocoa may reduce fatigue; however, the effect 2 
on fatigue in people with MS (pwMS) has never been established. The objective of this 3 
feasibility study was to explore the acute effect of high flavonoid cocoa on measures of 4 
fatigue and glycaemic response. Methods: This was a randomised crossover participant blind 5 
exploratory study in 12 participants (2 male and 10 female) with MS-related fatigue (>4 on 6 
the Fatigue Severity Scale; FSS).  After fasting overnight, participants consumed the high 7 
flavonoid cocoa drink (350 mg gallic acid equivalents {GAE}/g) or a low flavonoid cocoa 8 
control (120 mg GAE/g), consuming the alternative drink on the next visit.  Fatigue was self-9 
reported on a 100mm visual analogue scale at 30-minute time intervals for 2 hours post cocoa 10 
consumption and every 2 hours for the rest of the day. Fatigability was monitored using a 6 11 
minute walk test (6MWT) at the end of the visit (2 hrs), and activity monitors worn for 24 12 
hours commencing at 12noon on the day of testing. The feasibility of performing the trial 13 
including outcome measures was documented.  Results: A moderate effect was found in self-14 
reported fatigue throughout the day in favour of the high flavonoid group (Cohen’s d 0.32, 15 
95% non-central t CI -0.57-1.20). Fatigability measures did not change. Participants 16 
consumed and enjoyed the cocoa, all participants completed the study and outcome measures 17 
were accepted. Conclusion: The results of this study support further trials to investigate the 18 
feasibility and efficacy of pure cocoa as a dietary supplement for fatigue in pwMS. 19 
 20 
Abbreviations 21 
BG, blood glucose; GR, glycaemic response; VAS, visual analogue scale; GAE, gallic acid 22 
equivalents; pwMS, people with Multiple Sclerosis; FFQ, food frequency questionnaire; BI, 23 
Barthels Index; FSS, fatigue severity scale  24 
Introduction 25 
Fatigue is one of the most debilitating symptoms in people with Multiple Sclerosis (pwMS), 26 
greatly affecting quality of life (Tabrizi and Radfar, 2015). The exact cause of fatigue in MS 27 
is unknown, however various mechanisms may influence fatigue severity.  28 
Foods rich in flavonoids may show potential for reducing fatigue, through several 29 
proposed mechanisms. There is currently available evidence that suggests oxidative stress 30 
may contribute to the pathology in MS, which in turn may be improved or inhibited by the 31 
antioxidant properties in flavonoids (van Horssen et al., 2008). In addition, it has been 32 
suggested that the functional properties of flavonoids allow for penetration through the blood-33 
brain barrier, potentially leading to improved neurosignaling, as well as rehabilitation of 34 
neuronal function (Solanki et al., 2015). A pathological inflammatory response may be 35 
responsible for the fatigue experienced in MS, for example TNF-alpha levels have been found 36 
to be elevated in fatigued pwMS compared to those who were non fatigued (Braley and 37 
Chervin, 2010).  Luteolin, a naturally occurring flavonoid,  has been found to benefit the 38 
disease course of pwMS, for example by inhibiting activated  peripheral blood leukocytes and 39 
mast cells and mast cell dependent T cell activation (Theoharides, 2009). Katz, Doughty and 40 
Ali (2011) suggest that cocoa may be beneficial towards MS remission as its flavonoid 41 
content may promote blood flow to the brain, and may therefore lead to additional nerve 42 
repair, better metabolic clearance from the brain and greater oxygen availability.  Therefore 43 
foods containing flavonoids may be used in conjunction with other disease modifying 44 
treatments (DMTs) in pwMS to reduce relapses and improve the severity of the symptoms 45 
experienced. 46 
Cocoa is rich in flavonoids and is a popular and easily accessible product.  A recent 47 
systematic review and meta-analysis investigated 42 randomized control trials, and found 48 
cocoa to be significantly beneficial for vascular endothelial function and inflammation 49 
(Hooper et al., 2012). Cocoa has been shown to improve fatigue in people with Chronic 50 
Fatigue Syndrome (CFS). Sathyapalan et al. (2010) conducted a double blinded, randomised, 51 
pilot crossover study, daily providing participants with 45g of high flavonoid chocolate. After 52 
eight weeks participants reported significant reductions in fatigue and disability. Poor sleep 53 
quality has previously been shown to be significantly correlated with fatigue in MS (Attarian 54 
et al., 2004). Flavonoids have also been shown to improve sleep quality and therefore may 55 
reduce daytime fatigue in those with MS (Ngan & Cunduit, 2011). 56 
Flavonoid rich foods have also been shown to influence postprandial blood glucose 57 
levels (Coe et al. 2013). Glucose tolerance may be altered in pwMS (Mahler et al., 2012; 58 
Wens et al. 2013; White et al., 2006) and an association has been found between the 59 
availability of glucose to the brain and perceived fatigue (Roelcke et al., 1997). This has 60 
therefore raised the question as to whether improved glucose tolerance may reduce the 61 
fatigue experienced in those with the disease. However to date there has been no exploration 62 
of the response in this group. 63 
The current randomised crossover exposure response participant blind exploratory 64 
study will assess the effect of high flavonoid cocoa versus low flavonoid cocoa on fatigue 65 
and fatigability as measured by mobility in pwMS. Glycaemic response (GR) after the 66 
consumption of the drink, was also measured. 67 
 68 
  69 
Method 70 
This was a randomised crossover participant blind exploratory study in 12 participants (aged 71 
54 ± 10.56 years, 2 male and 10 female) with MS-related fatigue.  Participants were expected 72 
to attend two test visits at Oxford Brookes University and in a randomised order (determined 73 
electronically by a random number table) consumed either the low flavonoid control or the 74 
high flavonoid cocoa on different days, with at least three days between test visits (Figure 1). 75 
The present study was approved by the Oxford Brookes University Research Ethics 76 
Committee: UREC Registration No: 150938. All procedures were carried out accordingly to 77 
Declaration of Helsinki guidelines and policies, and retained data was managed accordingly 78 
to the Oxford Brookes University’s policy on Academic Integrity. 79 
 80 
Procedure  81 
PwMS were recruited from local support groups throughout the Thames Valley and via 82 
advertisements posted at Oxford Brookes University. After expressing interest in the study, 83 
participants where provided with the study information sheet and were given a minimum of 84 
24 hours to review the information and ask the researchers any questions regarding the trial.  85 
Once potential participants agreed to take part in the trial and after initial eligibility was 86 
checked over the phone, a combined screening and first test visit was arranged where signed 87 
consent was taken.  88 
Participants were asked to keep a 24 hour food diary the day before each visit, and to 89 
repeat this diet before the next test day. In addition to reduce variability in testing, 90 
participants were also asked to avoid vigorous exercise, and to limit their alcohol and caffeine 91 
intake on the day prior to testing (≤ 2 units and ≤ 3 cups respectively). Additionally, 92 
participants were asked to fast overnight for 10 – 12 hours prior to visits, which began 93 
between 7-10 am, and on the first assessment visit a health questionnaire was administered 94 
(asking about smoking habits, current or previous diseases, current medication or supplement 95 
intake, dietary habits).  96 
 97 
Screening and descriptive data 98 
At the screening/ first test visit demographics were recorded including MS subtype, 99 
compliance with the fasting protocol, blood pressure (mmHg) was recorded and mean fasting 100 
blood glucose (BG) was measured. Participant independence in daily living was assessed 101 
using the Barthels Index (BI; Nicholl et al., 2004). Each test occasion lasted no longer than 102 
three hours, and participants were required to leave a minimum of 24 hours between test 103 
days. 104 
 105 
Participants  106 
Participants were excluded if they reported any sudden changes in MS symptoms 107 
within the last three months, had a change in their DMTs and/ or medications that could 108 
influence fatigue in the past three weeks, had a metabolic disease or were presently on 109 
medication interfering with insulin or glucose metabolism, had been diagnosed with a 110 
condition other than MS affecting the CNS, had an allergy or intolerance to ingredients used 111 
during testing, experienced fatigue from any condition other than MS, were pregnant or 112 
lactating, were clinically depressed, had a BMI outside 18.5 - 30 kg/m² (body composition 113 
was confirmed using Tanita BC-418MA), had impaired glucose tolerance (7.8-11.1 mmol/L), 114 
or had a fatigue severity score less than 4 on the Fatigue Severity Scale (FSS; Krupp et al. 115 
1989). This scale asks nine questions about various aspects of perceived fatigue, 1 = not 116 
fatigued at all and 7 = very fatigued.  117 
 118 
Acute response to flavonoid drink/ intervention  119 
Participants were randomly administrated a high polyphenol test or low polyphenol control 120 
cocoa drink (Table 1), to consume within a maximum time of 15 minutes. Drinks were 121 
matched as closely as possible for available carbohydrate (avCHO) and energy content. Due 122 
to the idea that pwMS are following the Overcoming Multiple Sclerosis (OMS) diet, which 123 
excludes diary from the diet, the drink was made with Alpro rice milk (Tesco, UK). The total 124 
polyphenol content of the drinks had previously been established (Santos and Coe, 2016), 125 
with the high flavonoid cocoa powder containing 350mg gallic acid equivalents (GAE)/g, 126 
whilst the low flavonoid control powder had instead been established to contain 120mg 127 
GAE/g. 128 
 129 
Fatigue VAS 130 
Fatigue was recorded on a horizontal 100mm VAS every 30 minutes following drink 131 
consumption and throughout testing, categorizing 0mm as ‘not at all fatigued’ and 100mm as 132 
‘extremely fatigued’ (Kos et al., 2006). Participants continued to record fatigue every two 133 
hours after testing was completed, until six hours after leaving the lab.  134 
 135 
Fatigability 136 
Fatigability was monitored using a 6 minute walk test (6MWT) performed at the end of the 137 
visit (2 hrs), and through activity monitoring.   138 
 139 
Activity monitoring  140 
A GENEActiv (Geneactive, UK) was used to record physical activity for a 24 hour period. 141 
Data was sampled at 100Hz at a +/-8g range at 3.9mg resolution and recorded from the non-142 
dominant wrist. Post measurement, data was epoched to 1seconds samples and analysed in a 143 
bespoke spreadsheet (Excell, Microsoft Office 2011, US) and expressed as percentages of 144 
physical activity level (sedentary, light, moderate, vigorous) per hour, according to sample 145 
frequency adjusted Single Vector Magnitude cut-offs described by Esliger et al. (2011). 146 
 147 
6 Minute Walk Test 148 
The 6MWT has previously been proved to be an accurate tool to establish physical fatigue in 149 
MS (Goldman, Marrie and Cohen, 2008). On each test occasion, the 6MWT was performed 150 
approximately 120 minutes after the test meal was consumed. Participants were instructed to 151 
walk back and forth along a 14m long corridor at a pace they deemed comfortable, rounding 152 
a cone at the end of each lap. During the walk, participants were at all times accompanied by 153 
appropriately trained personnel, and were informed they may stop and rest if needed. The 154 
walk was timed using a hand held stopwatch and distance walked was measured in metres.  155 
 156 
GR 157 
GR was measured using the previously validated method of Wolever (2004) and redesigned 158 
by Coe et al. (2013), and is in line with procedures recommended by the Food and 159 
Agriculture Organization/World Health Organization.  A total of eight blood measures were 160 
taken using an automatic blood glucose analyser (Glucose 201+, Hemocue AB, Sweden).  161 
Mean fasting BG was calculated using two 5µl finger-prick samples at -5 and 0 min, and 162 
measurements were collected at 15, 30, 45, 60, 90 and 120 minutes after the cocoa 163 
consumption.  BG levels were compared to WHO guidelines to determine if any of the 164 
participants had fasting BG or postprandial BG values outside of the healthy range. 165 
 166 
Statistical Analysis 167 
This trial was not designed to determine efficacy and therefore no formal sample size 168 
calculation was under taken. Descriptive statistics were expressed, including demographic 169 
characteristics.  170 
Fatigue raw data, and GR-AUC data was calculated using a fixed effects model with 171 
two treatments (control versus test) adjusted using the Tukey-Kramer and comparing time 172 
and treatment interaction. GR VAS AUC was calculated geometrically using the trapezoidal 173 
rule at each time point relative to baseline values (Wolever, 2004). For outcome data the 174 
Linear Mixed Models (LMM) procedure of SAS 9.4 was used to determine the mean changes 175 
in measures, as response variables, according to exposures (test and control) and three 176 
repeated measurements, using baseline as a covariate. Further and based on the differences of 177 
LS (Marginal) means between two groups (test versus control; pairwise comparisons), 178 
provided by LMM analysis, powers, effect sizes (Cohen’s d) and their 95% non-central 179 
confidence limits were calculated. 180 
For physical activity, a model with time as a repeated factor, a treatment factor with 181 
two levels (placebo and test) and 3rd factor with 3 levels (sedentary, light, moderate and 182 
vigorous) was considered. Day and night required introduction of one more factor with two 183 
levels (day and night). Activity data was aggregated over 6 hours (4 levels) for sedentary, 184 
light and moderate activity. Activity awake versus sleep data was aggregated for day and 185 
night (2 levels).  A random effect model aggregated for total activities with sequence 186 
incorporated.  187 
 188 
  189 
Results  190 
 191 
A summary of descriptive data may be viewed in Table 2. Participants who had had 192 
MS for a number of years presented with relapsing remitting, primary and secondary 193 
progressive subtypes. All were high functioning and independent in daily activities.  As can 194 
be seen in Table 2 four out of the 12 participants were on special diets, three of who were on 195 
the OMS diet, and one on a gluten free diet. Seven people were taking Vitamin D 196 
supplements.  Two participants reported daily taking the antidepressant medication 197 
Amitriptyline (10mg and 50mg) and two additional participants reported currently taking 198 
drugs for fatigue including Modafinil and Amandatine (200mg and 100mg). 199 
No adverse events or side-effects were reported or observed during this study and all 200 
participants finished the drink on all occasions.  Participants were overall content with the 201 
taste and sensory properties of the drink, none reported a dislike of the drink. Participants 202 
seemed to find it feasible to comply to consuming a relatively similar diet the day before each 203 
test day. 204 
 205 
Fatigue Visual Analogue Scales 206 
A moderate effect was found in self-reported fatigue throughout the day in favour of the high 207 
flavonoid group post consumption (Cohen’s d 0.32, 95% non-central t CI -0.57-1.20). Figure 208 
2 indicates a trend for fatigue to be reduced in the hours after leaving the lab through until 209 
evening. 210 
 211 
Activity monitoring 212 
There was more activity during the sleeping hours (10pm-9am) after the consumption of the 213 
low flavonoid compared to the high flavonoid drink (Figure 3). Moderate physical activity 214 
tended to be higher five hours post high flavonoid cocoa consumption compared to moderate 215 
physical activity after the control (Cohen’s d 0.47, 95% CI: -0.36-1.27).  216 
 217 
6 Minute Walk Test 218 
All participants completed the 6MWT on both visits. There was a wide range in distance 219 
walked with an average of 273±115m, ranging from 120 – 475m (Figure 4). This was 220 
expected due to the varied levels of disability among the participants, of which three needed 221 
the assistance of an aid (cane or frame) to complete the walk.  222 
 223 
Glycaemic Response 224 
All participants had normal fasting BG levels and 2 hour postprandial BG levels as defined 225 
by the WHO (diabetes if fasting BG of >7.0 mmol/l or 2 hour postprandial BG >11.1 mmol/l 226 
and impaired glucose tolerance if fasting BG >7.0 mmol/l and 2 hour postprandial BG >7.8 227 
and <11.1 mmol/l); however two participants were exclude from the analysis due to 228 
abnormally high BG levels at time points between 0-120 mins. There was a trend for the high 229 
flavonoid cocoa to slightly decrease GR in the early stages postprandial (Cohen’s d - 0.07, 230 
95% t CI -94-0.81; Figure 5).   231 
Discussion  232 
 233 
The results of this trial ultimately show that a single drink of flavonoid rich cocoa produced a 234 
modest effect size reduction in perceived fatigue ratings compared to a low flavonoid control 235 
drink. This is the first study in pwMS to explore flavonoid use as a treatment for fatigue. The 236 
positive effect on fatigue alongside good tolerance and no adverse effects support the need 237 
for a powered trial of the longer-term effects. The results of the study may help direct future 238 
studies to identify specific questions and employ more efficient designs. 239 
A single dose of flavonoids produced a modest effect on fatigability as measured the 240 
24 hour activity levels yet showed no impact on the 6MWT. Specifically, later in the day five 241 
hours after cocoa consumption an effect was observed in activity levels.  However, 242 
performance on these mobility measures will have been affected by a number of other 243 
biopsychosocial factors and it may have been that the 6MWT was administered too early to 244 
see an effect on activity levels. In the current study there was a trend for activity during the 245 
day to be greater after the high flavonoid cocoa consumption, and activity during the sleeping 246 
hours was less. This observation is a positive observation as both poor sleep quality and 247 
reduced physical activity are common in MS (Attarian et al., 2004) and a number of 248 
participant’s commented on poor sleep quality the night before testing.  249 
Moreover, the fatigue VAS does not differentiate between primary fatigue which is a 250 
direct result of the disease, and secondary fatigue which is a result of other symptoms. High 251 
flavonoid cocoa has previously been shown to improve factors which may lead to secondary 252 
fatigue such as sleep quality, and it may be speculated a further frequent intake of high 253 
flavonoid cocoa may allow for the beneficial mechanisms to take effect, possibly reducing 254 
secondary fatigue while allowing for improved fatigue VAS accuracy (Bisson et al., 2008). 255 
Also from assessing the activity data, participants overall seemed to perform low levels of 256 
physical activity and spent a majority of their time in sedentary/ light activity. Therefore 257 
although further studies would need to be performed, it appears that high flavonoid cocoa 258 
may contribute to improving physical activity during the day and better sleep patterns at night 259 
in those with MS.  260 
This was a one-day study which may not have been long enough to produce a larger 261 
effect. Sathyapalan et al. (2010) administered high flavonoid cocoa daily over a period of 262 
eight weeks to find significant differences. A meta-analysis of Hooper et al. (2012) similarly 263 
suggests positive changes to health may depend on the quantity of cocoa consumed. The dose 264 
of polyphenols present in the high flavonoid drink in the current study may have been a 265 
limitation as the drinks contained 350 mg of gallic acid equivalents (GAE)/g and 120 mg 266 
GAE/g for the high flavonoid and low flavonoid beverages, respectively.  In Field et al. 267 
(2011), on results obtained for spatial memory and performance on aspects of choice reaction 268 
time task, high flavonoid cocoa containing 773 mg flavonoids was used, with significant 269 
results found compared to the control (low flavonoid cocoa).   270 
The underlying mechanisms were not fully explored in this acute response to a single 271 
dose trial; however, foods rich in flavonoids have been shown to stabilise postprandial BG 272 
levels (Davies et al., 2012) and consequently reduce fatigue in healthy individuals (Micha et 273 
al., 2011).  In this study there was no effect of dark cocoa on BG, however there was a trend 274 
for the high flavonoid cocoa to reduce the BG in the early stages after consumption and 275 
stabilise levels later after consumption. Although all participants showed normal BG levels as 276 
defined by WHO, there were some abnormally high patterns in GR during the two hours after 277 
the cocoa drink consumption. Therefore the GR in people with MS should be considered in 278 
future trials when assessing nutrition and fatigue, and the effect of pure cocoa on fasting BG 279 
would need further exploration.    280 
Diet has recently been shown to be an important factor in influencing clinical 281 
outcomes in MS (Grossman & Wahls, 2016). Research has found that pwMS are not only 282 
willing to consider dietary approaches to manage their symptoms (Brenton & Goldman, 283 
2016) yet many are already on various diets in order to do so (Schwarz et al., 2008). It was 284 
therefore hypothesised that this population would be more open to a dietary intervention.  285 
Indeed results show that four out of 12 participants were on special diets for their condition, 286 
and seven were taking some form of Vitamin D supplements.  287 
Although not for managing depression, two participants reported daily intake of the 288 
antidepressant drug Amitriptyline (50 and 10mg), while two additional participants reported 289 
currently taking drugs for fatigue including Modafinil and Amandatine (200mg and 100mg). 290 
Amitriptyline has previously been shown to cause sleepiness, as well as drowsiness in 291 
patients (Frost et al., 2011). Contrastively, Modafinil and Amandatine have previously been 292 
reported to decrease fatigue (Ashtari et al., 2009, Brown et al., 2010). Therefore these 293 
medications may have increased variability and decreased ability to see a difference in 294 
results. However, pwMS are on these medications and therefore the study is more reflective 295 
of real world practice.  296 
No participants in the trial vocalised issues with the outcome measures or with the 297 
fasting protocol. From the accelerometer results, it seemed that participants wore the watch 298 
for the entire testing period. Overall we propose that the flavonoid cocoa drink was well 299 
tolerated and enjoyed by all participants and is both suitable for a trial of longer term use and 300 
feasible that this drink would be consumed as part of a daily diet.  There were no adverse 301 
events, and all participants completed the study. Participants were compliant with the study 302 
protocol and approved of outcome measures.  This, in combination with the moderate effect 303 
size on reducing fatigue, shows promise for further studies into the role of flavonoid rich 304 
cocoa on fatigue in MS. 305 
 306 
Limitations 307 
Due to the novel and exploratory nature of the study a pragmatic approach was used 308 
determine sample size and no formal sample size calculation was under taken. However, post 309 
hoc analysis found moderate effect sizes at measurement points where differences in fatigue 310 
were greatest in the high flavonoid group.  311 
In the current study, whilst the participants were, assessors were not blinded to the 312 
intervention. However, the protocol was delivered in randomised format and according to 313 
fixed standardised operating instruction sets and procedures. Also a number of measures 314 
including the accelerometer data and the fatigue ratings were recorded at home following the 315 
test day. Furthermore all data processing was performed blinded and a statistician blinded to 316 
the groupings performed analysis. The inclusion/ exclusion criteria in this study was very 317 
broad including those with all types of MS and on any medication for their condition and/ or 318 
other health conditions (excluding glycaemic control medication). Therefore the 319 
heterogeneity of the participant characteristics in addition to the small sample size may have 320 
reduced the observed effect. However the study enabled the procedures to be tested across 321 
subtypes and establish a follow on study as feasible. 322 
  323 
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